Exact Mass: 383.1566668

Exact Mass Matches: 383.1566668

Found 147 metabolites which its exact mass value is equals to given mass value 383.1566668, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Prazosin

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine

C19H21N5O4 (383.15934660000005)


Prazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma. C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents KEIO_ID P191; [MS2] KO009165 Corona-virus KEIO_ID P191 Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic blocker that is specific for the alpha-1 receptors. These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.In addition to its alpha-blocking activity, prazosin is an antagonist of the MT3 receptor (which is not present in humans), with selectivity for this receptor over the MT1 and MT2 receptors. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is initially started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.

   

Meropenem

Meropenem

C17H25N3O5S (383.15148400000004)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Meropenem (SM 7338) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL)[1][2].

   

Niazimin

(2S,3R,4S,5R,6S)-6-(4-{[(ethoxycarbonyl)amino]methyl}phenoxy)-4,5-dihydroxy-2-methyloxan-3-yl acetate

C18H25NO8 (383.158009)


Niazimin is a glucosinolate and a naturally occurring carbamate. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. The cis and trans rotamers of niazimin (niazimin A and niazimin B, respectively) differ in the orientation of the NH group with respect to the carbonyl group. Constituent of Moringa oleifera (horseradish tree). Niazimin A is found in fats and oils, herbs and spices, and green vegetables.

   

Meropenem

(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C17H25N3O5S (383.15148400000004)


Meropenem is only found in individuals that have used or taken this drug.It is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets and interfere with the synthesis of the vital cell wall components, which leads to cell death. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D013845 - Thienamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Meropenem (SM 7338) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL)[1][2].

   

3-[5-(Dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

3-{[5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulphanyl}-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C17H25N3O5S (383.15148400000004)


   

N-[(1R)-2,3-Dihydro-1H-inden-1-yl]-adenosine

2-{6-[(2,3-dihydro-1H-inden-1-yl)amino]-9H-purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol

C19H21N5O4 (383.15934660000005)


   

3-((2'-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

4-({2-cyclopropyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl}methyl)-[1,1-biphenyl]-2-carboxylic acid

C24H21N3O2 (383.1633686)


   

LEUCOGENENOL

2-(1,2-dihydroxy-3-methyl-5-oxocyclohexyl)-3,11-dihydroxy-11-(hydroxymethyl)-9-methyl-1-oxa-5-azaspiro[5.5]undeca-2,4-dien-7-one

C18H25NO8 (383.158009)


   

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate

methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazol-3-yl}formamido)-3-methylbutanoate

C21H22FN3O3 (383.16451140000004)


   

VERALIPRIDE

2,3-Dimethoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-5-sulphamoylbenzene-1-carboximidic acid

C17H25N3O5S (383.15148400000004)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.

   

Niazimin A

N-[(4-{[5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidate

C18H25NO8 (383.158009)


Constituent of Moringa oleifera (horseradish tree). Niazimin A is found in fats and oils, herbs and spices, and green vegetables.

   
   

1-[1-(3,4-Dichlorobenzamidomethyl)cyclohexyl]-4-methylpiperazine

1-[1-(3,4-Dichlorobenzamidomethyl)cyclohexyl]-4-methylpiperazine

C19H27Cl2N3O (383.1531072)


   
   

12,13,19-trihydroxy-15,20-epoxy-15,20-dihydro, (12S,15R,20R)senecionan-11,16-dione|15,20-Epoxy-15,20-dihydro-12,13,19-trihydroxy-11,16-senecionanedione|Adonifoline

12,13,19-trihydroxy-15,20-epoxy-15,20-dihydro, (12S,15R,20R)senecionan-11,16-dione|15,20-Epoxy-15,20-dihydro-12,13,19-trihydroxy-11,16-senecionanedione|Adonifoline

C18H25NO8 (383.158009)


   

6-[(Isopropyloxy)methyl]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one

6-[(Isopropyloxy)methyl]-6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one

C24H21N3O2 (383.1633686)


   

9H-Purin-6-amine, N-(3-methylbutyl)-2-(methylthio)-9-pentofuranosyl-

9H-Purin-6-amine, N-(3-methylbutyl)-2-(methylthio)-9-pentofuranosyl-

C16H25N5O4S (383.16271700000004)


   
   
   

prazosin

prazosin

C19H21N5O4 (383.15934660000005)


C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CA - Alpha-adrenoreceptor antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS relative retention time with respect to 9-anthracene Carboxylic Acid is 0.767 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.759 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.760 Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder. Target: Adrenergic Receptor Prazosin, is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, andpanic disorder. It is an alpha-adrenergic blocker that is specific for the alpha-1 receptors. These receptors are found on vascular smooth muscle, where they are responsible for the vasoconstrictive action of norepinephrine. They are also found throughout the central nervous system. As of 2013, prazosin is off-patent in the US, and the FDA has approved at least one generic manufacturer.In addition to its alpha-blocking activity, prazosin is an antagonist of the MT3 receptor (which is not present in humans), with selectivity for this receptor over the MT1 and MT2 receptors. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is initially started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases.

   

VERALIPRIDE

VERALIPRIDE

C17H25N3O5S (383.15148400000004)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.

   

Gly Gly His Asn

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

C14H21N7O6 (383.15532460000003)


   

Gly Gly Asn His

(2S)-2-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C14H21N7O6 (383.15532460000003)


   

Gly His Gly Asn

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-carbamoylpropanoic acid

C14H21N7O6 (383.15532460000003)


   

Gly His Asn Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]acetic acid

C14H21N7O6 (383.15532460000003)


   

Gly Asn Gly His

(2S)-2-{2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]acetamido}-3-(1H-imidazol-4-yl)propanoic acid

C14H21N7O6 (383.15532460000003)


   

Gly Asn His Gly

2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]acetic acid

C14H21N7O6 (383.15532460000003)


   

His Gly Gly Asn

(2S)-2-(2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}acetamido)-3-carbamoylpropanoic acid

C14H21N7O6 (383.15532460000003)


   

His Gly Asn Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-carbamoylpropanamido]acetic acid

C14H21N7O6 (383.15532460000003)


   

His Asn Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]acetamido}acetic acid

C14H21N7O6 (383.15532460000003)


   

Asn Gly Gly His

(2S)-2-(2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}acetamido)-3-(1H-imidazol-4-yl)propanoic acid

C14H21N7O6 (383.15532460000003)


   

Asn Gly His Gly

2-[(2S)-2-{2-[(2S)-2-amino-3-carbamoylpropanamido]acetamido}-3-(1H-imidazol-4-yl)propanamido]acetic acid

C14H21N7O6 (383.15532460000003)


   

Asn His Gly Gly

2-{2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]acetamido}acetic acid

C14H21N7O6 (383.15532460000003)


   

Niazimin A

6-(4-{[(ethoxycarbonyl)amino]methyl}phenoxy)-4,5-dihydroxy-2-methyloxan-3-yl acetate

C18H25NO8 (383.158009)


   

PD 117519

PD 117519

C19H21N5O4 (383.15934660000005)


PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2]. PD 117519 (CI947) is an A2A adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2].

   

3-Methyl-2-(tributylstannyl)pyridine

3-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1634848)


   

5-Methyl-2-(tributylstannyl)pyridine

5-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1634848)


   

4-Methyl-2-(tributylstannyl)pyridine

4-Methyl-2-(tributylstannyl)pyridine

C18H33NSn (383.1634848)


   

2-Methyl-6-(tributylstannyl)pyridine

2-Methyl-6-(tributylstannyl)pyridine

C18H33NSn (383.1634848)


   

3-((2-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

3-((2-Carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine

C24H21N3O2 (383.1633686)


D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers

   

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-DL-valinate

Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-DL-valinate

C21H22FN3O3 (383.16451140000004)


   

N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine

N-(4-Aminobutanoyl)-S-(4-methoxybenzyl)-L-cysteinylglycine

C17H25N3O5S (383.15148400000004)


   

N-[2-(1-Maleimidyl)ethyl]-7-diethylaminocoumarin-3-carboxamide

N-[2-(1-Maleimidyl)ethyl]-7-diethylaminocoumarin-3-carboxamide

C20H21N3O5 (383.14811360000004)


   

(1s,5s,7r)-N~7~-(Biphenyl-4-Ylmethyl)-N~3~-Hydroxy-6,8-Dioxa-3-Azabicyclo[3.2.1]octane-3,7-Dicarboxamide

(1s,5s,7r)-N~7~-(Biphenyl-4-Ylmethyl)-N~3~-Hydroxy-6,8-Dioxa-3-Azabicyclo[3.2.1]octane-3,7-Dicarboxamide

C20H21N3O5 (383.14811360000004)


   

beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine

beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine

C14H27N2O10+ (383.1665622)


   

N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosaminium(1+)

N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosaminium(1+)

C14H27N2O10+ (383.1665622)


   

(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-1-ium-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-1-ium-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

C17H25N3O5S (383.15148400000004)


   

2-(3,5-Diphenyl-3,4-dihydropyrazol-2-yl)-2-(4-hydroxy-3-methoxyphenyl)acetonitrile

2-(3,5-Diphenyl-3,4-dihydropyrazol-2-yl)-2-(4-hydroxy-3-methoxyphenyl)acetonitrile

C24H21N3O2 (383.1633686)


   

3-(1-methyl-1H-pyrrol-2-yl)-N-[(E)-(2,4,5-trimethoxyphenyl)methylidene]-1H-pyrazole-5-carbohydrazide

3-(1-methyl-1H-pyrrol-2-yl)-N-[(E)-(2,4,5-trimethoxyphenyl)methylidene]-1H-pyrazole-5-carbohydrazide

C19H21N5O4 (383.15934660000005)


   

6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine

6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine

C24H21N3O2 (383.1633686)


   

2-(3-isopropyloxyphenyl)-N-(pyridin-4-yl)quinoline-4-carboxamide

2-(3-isopropyloxyphenyl)-N-(pyridin-4-yl)quinoline-4-carboxamide

C24H21N3O2 (383.1633686)


   

16alpha-Hydroxydehydroepiandrosterone 3-sulfate(1-)

16alpha-Hydroxydehydroepiandrosterone 3-sulfate(1-)

C19H27O6S- (383.15282620000005)


A steroid sulfate oxoanion that is the conjugate base of 16alpha-hydroxydehydroepiandrosterone 3-sulfate, arising from deprotonation of the sulfate OH group; major species at pH 7.3.

   

N-(1,3-benzodioxol-5-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide

N-(1,3-benzodioxol-5-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide

C20H21N3O5 (383.14811360000004)


   

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.15148400000004)


   

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.15148400000004)


   

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.15148400000004)


   

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.15148400000004)


   

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.15148400000004)


   

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.15148400000004)


   

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.15148400000004)


   

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3-oxanyl]-4-oxanecarboxamide

C17H25N3O5S (383.15148400000004)


   

5-Amino-5-(4-hydroxybenzyl)-6-((2,3,4,5-tetrahydroxypentyl)amino)dihydropyrimidine-2,4-dione(1+)

5-Amino-5-(4-hydroxybenzyl)-6-((2,3,4,5-tetrahydroxypentyl)amino)dihydropyrimidine-2,4-dione(1+)

C16H23N4O7+ (383.1566668)


   

(4R,5S,6R)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

(4R,5S,6R)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C17H25N3O5S (383.15148400000004)


   

3-[5-(Dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

3-[5-(Dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

C17H25N3O5S (383.15148400000004)


   
   

9-hydroxy-9-(1-hydroxyethyl)-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione

9-hydroxy-9-(1-hydroxyethyl)-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione

C18H25NO8 (383.158009)


   

8-[4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one

8-[4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one

C24H21N3O2 (383.1633686)


   

13-(isopropoxymethyl)-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),17(22),18,20-nonaen-12-one

13-(isopropoxymethyl)-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),17(22),18,20-nonaen-12-one

C24H21N3O2 (383.1633686)


   

(5s,7r,9r,12r,18r)-9-hydroxy-9-[(1s)-1-hydroxyethyl]-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione

(5s,7r,9r,12r,18r)-9-hydroxy-9-[(1s)-1-hydroxyethyl]-7-(hydroxymethyl)-5-methyl-3,6,11-trioxa-15-azatetracyclo[10.5.1.0⁵,⁷.0¹⁵,¹⁸]octadec-1(17)-ene-4,10-dione

C18H25NO8 (383.158009)


   

n-[(4-{[(2s,3r,4s,5r,6s)-5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

n-[(4-{[(2s,3r,4s,5r,6s)-5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

C18H25NO8 (383.158009)


   

6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione

6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione

C18H25NO8 (383.158009)


   

(1'r,2r,3r,6'r,7's,17'r)-6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione

(1'r,2r,3r,6'r,7's,17'r)-6',7'-dihydroxy-6'-(hydroxymethyl)-3,7'-dimethyl-2',9'-dioxa-14'-azaspiro[oxirane-2,4'-tricyclo[9.5.1.0¹⁴,¹⁷]heptadecan]-11'-ene-3',8'-dione

C18H25NO8 (383.158009)


   

(7s,8z)-8-[(3e)-4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one

(7s,8z)-8-[(3e)-4-(1h-indol-3-yl)-2-oxobut-3-en-1-ylidene]-3,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),10,12-trien-2-one

C24H21N3O2 (383.1633686)


   

n-[(4-{[5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

n-[(4-{[5-(acetyloxy)-3,4-dihydroxy-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

C18H25NO8 (383.158009)